B-Harmony: WuXi And MedImmune Establish JV To Seize Biologics Growth In China
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi’s joint venture with MedImmune could have ripple effects for other multinational biotechs aiming to develop biologics for China.
You may also be interested in...
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.